Tumor-suppressive pathways in pancreatic carcinoma

Ester Rozenblum, Mieke Schutte, Michael Goggins, Stephan A. Hahn, Shawn Panzer, Marianna Zahurak, Steven N. Goodman, Taylor A. Sohn, Ralph H. Hruban, Charles J. Yeo, Scott E. Kern

Research output: Contribution to journalArticle

583 Citations (Scopus)

Abstract

During tumorigenesis, positive selection is exerted upon those tumor cells that alter rate-limiting regulatory pathways. A corollary of this principle is that mutation of one gene abrogates the need for alteration of another gene in the same pathway and also that the coexistence in a single tumor of mutations in different genes implies their involvement in distinct tumor-suppressive pathways. We studied 42 pancreatic adenocarcinomas for genetic alterations in the K-ras oncogene and the p16, p53, and DPC4 tumor suppressor genes. All of them had the K-ras gene mutated. Thirty-eight % of the tumors had four altered genes, another 38% had three altered genes, 15% had two altered genes, and 8% of the tumors had one altered gone. Interestingly, we noted a high concordance of DPC4 and p16 inactivations (P = 0.007), suggesting that the genetic inactivation of p16 increases the selective advantage of subsequent mutation in DPC4. No statistically significant association was identified between the alteration of these cancer genes and pathological or clinical parameters. This type of multigenic analysis in human tumors may serve to substantiate experimental tumor models and thus increase our understanding of the truly physiologically relevant tumor-suppressive pathways that are abrogated during human tumorigenesis.

Original languageEnglish (US)
Pages (from-to)1731-1734
Number of pages4
JournalCancer Research
Volume57
Issue number9
StatePublished - May 1 1997
Externally publishedYes

Fingerprint

Neoplasms
Genes
ras Genes
Mutation
Carcinogenesis
Pancreatic Carcinoma
Neoplasm Genes
Tumor Suppressor Genes
Adenocarcinoma
Theoretical Models

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rozenblum, E., Schutte, M., Goggins, M., Hahn, S. A., Panzer, S., Zahurak, M., ... Kern, S. E. (1997). Tumor-suppressive pathways in pancreatic carcinoma. Cancer Research, 57(9), 1731-1734.

Tumor-suppressive pathways in pancreatic carcinoma. / Rozenblum, Ester; Schutte, Mieke; Goggins, Michael; Hahn, Stephan A.; Panzer, Shawn; Zahurak, Marianna; Goodman, Steven N.; Sohn, Taylor A.; Hruban, Ralph H.; Yeo, Charles J.; Kern, Scott E.

In: Cancer Research, Vol. 57, No. 9, 01.05.1997, p. 1731-1734.

Research output: Contribution to journalArticle

Rozenblum, E, Schutte, M, Goggins, M, Hahn, SA, Panzer, S, Zahurak, M, Goodman, SN, Sohn, TA, Hruban, RH, Yeo, CJ & Kern, SE 1997, 'Tumor-suppressive pathways in pancreatic carcinoma', Cancer Research, vol. 57, no. 9, pp. 1731-1734.
Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Research. 1997 May 1;57(9):1731-1734.
Rozenblum, Ester ; Schutte, Mieke ; Goggins, Michael ; Hahn, Stephan A. ; Panzer, Shawn ; Zahurak, Marianna ; Goodman, Steven N. ; Sohn, Taylor A. ; Hruban, Ralph H. ; Yeo, Charles J. ; Kern, Scott E. / Tumor-suppressive pathways in pancreatic carcinoma. In: Cancer Research. 1997 ; Vol. 57, No. 9. pp. 1731-1734.
@article{a2b0be90c31743c883092917a63cfabe,
title = "Tumor-suppressive pathways in pancreatic carcinoma",
abstract = "During tumorigenesis, positive selection is exerted upon those tumor cells that alter rate-limiting regulatory pathways. A corollary of this principle is that mutation of one gene abrogates the need for alteration of another gene in the same pathway and also that the coexistence in a single tumor of mutations in different genes implies their involvement in distinct tumor-suppressive pathways. We studied 42 pancreatic adenocarcinomas for genetic alterations in the K-ras oncogene and the p16, p53, and DPC4 tumor suppressor genes. All of them had the K-ras gene mutated. Thirty-eight {\%} of the tumors had four altered genes, another 38{\%} had three altered genes, 15{\%} had two altered genes, and 8{\%} of the tumors had one altered gone. Interestingly, we noted a high concordance of DPC4 and p16 inactivations (P = 0.007), suggesting that the genetic inactivation of p16 increases the selective advantage of subsequent mutation in DPC4. No statistically significant association was identified between the alteration of these cancer genes and pathological or clinical parameters. This type of multigenic analysis in human tumors may serve to substantiate experimental tumor models and thus increase our understanding of the truly physiologically relevant tumor-suppressive pathways that are abrogated during human tumorigenesis.",
author = "Ester Rozenblum and Mieke Schutte and Michael Goggins and Hahn, {Stephan A.} and Shawn Panzer and Marianna Zahurak and Goodman, {Steven N.} and Sohn, {Taylor A.} and Hruban, {Ralph H.} and Yeo, {Charles J.} and Kern, {Scott E.}",
year = "1997",
month = "5",
day = "1",
language = "English (US)",
volume = "57",
pages = "1731--1734",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Tumor-suppressive pathways in pancreatic carcinoma

AU - Rozenblum, Ester

AU - Schutte, Mieke

AU - Goggins, Michael

AU - Hahn, Stephan A.

AU - Panzer, Shawn

AU - Zahurak, Marianna

AU - Goodman, Steven N.

AU - Sohn, Taylor A.

AU - Hruban, Ralph H.

AU - Yeo, Charles J.

AU - Kern, Scott E.

PY - 1997/5/1

Y1 - 1997/5/1

N2 - During tumorigenesis, positive selection is exerted upon those tumor cells that alter rate-limiting regulatory pathways. A corollary of this principle is that mutation of one gene abrogates the need for alteration of another gene in the same pathway and also that the coexistence in a single tumor of mutations in different genes implies their involvement in distinct tumor-suppressive pathways. We studied 42 pancreatic adenocarcinomas for genetic alterations in the K-ras oncogene and the p16, p53, and DPC4 tumor suppressor genes. All of them had the K-ras gene mutated. Thirty-eight % of the tumors had four altered genes, another 38% had three altered genes, 15% had two altered genes, and 8% of the tumors had one altered gone. Interestingly, we noted a high concordance of DPC4 and p16 inactivations (P = 0.007), suggesting that the genetic inactivation of p16 increases the selective advantage of subsequent mutation in DPC4. No statistically significant association was identified between the alteration of these cancer genes and pathological or clinical parameters. This type of multigenic analysis in human tumors may serve to substantiate experimental tumor models and thus increase our understanding of the truly physiologically relevant tumor-suppressive pathways that are abrogated during human tumorigenesis.

AB - During tumorigenesis, positive selection is exerted upon those tumor cells that alter rate-limiting regulatory pathways. A corollary of this principle is that mutation of one gene abrogates the need for alteration of another gene in the same pathway and also that the coexistence in a single tumor of mutations in different genes implies their involvement in distinct tumor-suppressive pathways. We studied 42 pancreatic adenocarcinomas for genetic alterations in the K-ras oncogene and the p16, p53, and DPC4 tumor suppressor genes. All of them had the K-ras gene mutated. Thirty-eight % of the tumors had four altered genes, another 38% had three altered genes, 15% had two altered genes, and 8% of the tumors had one altered gone. Interestingly, we noted a high concordance of DPC4 and p16 inactivations (P = 0.007), suggesting that the genetic inactivation of p16 increases the selective advantage of subsequent mutation in DPC4. No statistically significant association was identified between the alteration of these cancer genes and pathological or clinical parameters. This type of multigenic analysis in human tumors may serve to substantiate experimental tumor models and thus increase our understanding of the truly physiologically relevant tumor-suppressive pathways that are abrogated during human tumorigenesis.

UR - http://www.scopus.com/inward/record.url?scp=14444284330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14444284330&partnerID=8YFLogxK

M3 - Article

C2 - 9135016

AN - SCOPUS:14444284330

VL - 57

SP - 1731

EP - 1734

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 9

ER -